2023年9月4日 · Olvimulogene nanivacirepvec (Olvi-Vec), with its strong immune modulating effect on the tumor microenvironment, may provide re-sensitization to platinum and clinically reverse platinum resistance or refractoriness in platinum-resistant/refractory ovarian cancer.

Olvimulogene nanivacirepvec (Olvi-Vec; aka GL-ONC1; laboratory name: GLV-1h68) is a modified oncolytic vaccinia virus that selectively infects malignant cells and replicates especially well in ovarian and lung cancers. 4 Because ovarian cancer usually metastasizes throughout the peritoneal cavity, it is amenable to intraperitoneal (IP ...

其中，Genelux公司的溶瘤病毒免疫疗法Olvi-Vec联合铂类化疗的卵巢癌试验已进入3期阶段，Replimune公司溶瘤病毒PR2联合PD-1抑制剂nivolumab和CTLA-4单抗ipilimumab治疗葡萄膜黑色素瘤的临床试验也迈入2/3期阶段。

In a previously completed clinical study, Olvi-Vec, systemically administered as a monotherapy in patients with advanced solid tumors and with no standard of care option, showed a dose-dependent clinical benefit on overall survival (OS) from …

2023年7月1日 · Objective: To assess antitumor activity and safety of intraperitoneal (IP) olvimulogene nanivacirepvec (Olvi-Vec) virotherapy and platinum-based chemotherapy with or without bevacizumab in patients with PRROC.

2022年9月26日 · The phase 3 OnPrime trial (NCT0528147, GOG-3076) evaluating the efficacy and safety of Olvi-Vec (olvimulogene nanivacirepvec), platinum-doublet chemotherapy, and bevacizumab (Avastin) compared with platinum-doublet chemotherapy plus bevacizumab has begun examining patients with platinum-resistant/refractory ovarian cancer, according to …

2023年11月28日 · The FDA has granted fast track designation (FTD) to olvimulogene nanivacirepvec (olvi-vec) for the treatment of patients with platinum-refractory/-resistant (R/R) ovarian cancer. 1 The FTD is supported by the phase 3 OnPrime/GOG-3076 study (NCT05281471).

2022年3月7日 · OnPrime 研究是一项多中心、随机、开放标签的第 3 期研究，评估 Olvi-Vec 后继以铂类双药化疗和贝伐珠单抗与活性比较臂与铂类双药化疗和贝伐珠单抗相比在诊断为患有铂耐药/...。

This Phase 3 study aims to test the hypothesis that the combination of Olvi-Vec followed by further platinum-doublet chemotherapy is particularly effective against tumors by virus-mediated immune activation and re-sensitization of tumor cells to chemotherapy in heavily pre-treated patients with platinum-resistant/refractory ovarian cancer ...

2022年12月6日 · This Phase 3 study aims to test the hypothesis that the combination of Olvi-Vec followed by further platinum-doublet chemotherapy is particularly effective against tumors by virus-mediated...